(Reuters) -Pfizer has signed a licensing agreement worth up to $6 billion with Chinese pharmaceutical products developer 3SBio Inc for the development, manufacturing and commercialization of a drug undergoing trials for treatment of certain types of cancer and tumours, the U.S. drugmaker said on Monday.
(Reporting by Kanjyik Ghosh; Editing by Alan Barona)
